sellWeak cluster of 410b5-1 plan
Alexandra Balcom sold $1.7M of NUVL
Chief Financial Officer at Nuvalent, Inc.. 20,000 shares at an average of $85.48, traded Oct 1, 2025, filed Oct 3, 2025.
Warning score
32Value
$1.7M
20,000 shares
Holdings after
61,734
-24% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +25Trade size$1.7M at market
- +5Share of holdings soldSold 24% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-230279, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2025 | MOption exercise Class A Common Stock10b5-1 | +16,787 | $6.89 | $116k | 78,521 | Oct 3, 2025 |
| Oct 1, 2025 | MOption exercise Class A Common Stock10b5-1 | +3,213 | $18.93 | $61k | 81,734 | Oct 3, 2025 |
| Oct 1, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -19,030 | $85.43 | $1.6M | 62,704 | Oct 3, 2025 |
| Oct 1, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -970 | $86.37 | $84k | 61,734 | Oct 3, 2025 |
| Oct 1, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -16,787 | $0.00 | $0 | 42,851 | Oct 3, 2025 |
| Oct 1, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,213 | $0.00 | $0 | 63,787 | Oct 3, 2025 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 17Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $2.5M 25,130 shares | -23% | |
| 23Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $721k 7,417 shares | -8% | |
| 44Moderate | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $782k 7,084 shares | -11% | |
| 12Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $434k 4,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Matthew Shair director | $820k 7,500 shares | -1% | |
| 55Moderate | Nuvalent, Inc. | James E Flynn director, owner, other | $71M 742,574 shares | -9% | |
| 37Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $2.1M 20,729 shares | -25% | |
| 30Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $2.6M 24,200 shares | -33% | |
| 30Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $2.2M 21,800 shares | -31% | |
| 11Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $412k 4,000 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.